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Abstract
Aim To quantify the association between behaviour change and weight loss after diagnosis of Type 2 diabetes, and the
likelihood of remission of diabetes at 5-year follow-up.
Method We conducted a prospective cohort study in 867 people with newly diagnosed diabetes aged 40–69 years from
the ADDITION-Cambridge trial. Participants were identified via stepwise screening between 2002 and 2006, and
underwent assessment of weight change, physical activity (EPAQ2 questionnaire), diet (plasma vitamin C and self-
report), and alcohol consumption (self-report) at baseline and 1 year after diagnosis. Remission was examined at 5 years
after diabetes diagnosis via HbA1c level. We constructed log binomial regression models to quantify the association
between change in behaviour and weight over both the first year after diagnosis and the subsequent 1–5 years, as well as
remission at 5-year follow-up.
Results Diabetes remission was achieved in 257 participants (30%) at 5-year follow-up. Compared with people who
maintained the same weight, those who achieved ≥ 10% weight loss in the first year after diagnosis had a significantly
higher likelihood of remission [risk ratio 1.77 (95% CI 1.32 to 2.38; p<0.01)]. In the subsequent 1–5 years, achieving
≥10% weight loss was also associated with remission [risk ratio 2.43 (95% CI 1.78 to 3.31); p<0.01].
Conclusion In a population-based sample of adults with screen-detected Type 2 diabetes, weight loss of ≥10% early in
the disease trajectory was associated with a doubling of the likelihood of remission at 5 years. This was achieved without
intensive lifestyle interventions or extreme calorie restrictions. Greater attention should be paid to enabling people to
achieve weight loss following diagnosis of Type 2 diabetes.
Diabet. Med. 37, 681–688 (2020)
Introduction
Type 2 diabetes affects 400 million people globally and has
been characterized as a lifelong progressive disease [1,2];
however, biochemical remission or ‘cure’, defined as a level
of glycaemia below the diagnostic threshold (HbA1c < 48
mmol/mol or 6.5%) [3] in the absence of pharmacological or
surgical interventions, is achievable through significant
calorie restriction and weight loss [4,5]. Although there are
varying definitions of remission in the literature, we have
adhered to that based on HbA1c levels in line with UK and
US national guidance [3]. Intensive low-calorie diet (total
energy intake of 624–700 kcal/day) for 8 weeks was
associated with remission in 87% of people with recently
diagnosed diabetes (<4 years) and in 50% of people with
longstanding disease (>8 years)[4]. Similarly, the Action for
Health in Diabetes (Look AHEAD) study included an
intensive 4-year programme, designed to increase physical
activity and reduce initial weight by ≥7% [6]. Participants
had a median diabetes duration of 5 years and, in the first
year after the intervention, 11.5% achieved partial or
complete remission compared to only 2.0% in the usual
care group. In the DIRECT trial, participants who had been
diagnosed with diabetes in the previous 6 years underwent an
intensive intervention, including withdrawal of diabetes and
blood pressure medication, diet replacement of 825–853
kcal/day through a formula diet for 3–5 months, stepped
food reintroduction (2–8 weeks), and structured support for
long-term weight loss maintenance [7]. Remission was
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achieved in 46% of the intervention group. Collectively,
these studies support the hypothesis that healthy behaviour
change and weight loss can result in remission of diabetes.
In all these studies, however, selected participants were
recruited to intensive weight loss interventions. Evidence is
therefore required from representative population-based
samples undergoing less intensive interventions that are
more feasible and potentially scalable to the wider popula-
tion. Furthermore, most studies have either examined remis-
sion in the short term or amongst people who have lived with
diabetes for a few years, or both [6,7]. It is unclear if
behaviour change and weight loss early in the disease
trajectory could lead to long-term remission. This is impor-
tant as there could be a window of opportunity following
diagnosis when people might be more receptive to interven-
tions concerning weight loss. Using data from the ADDI-
TION-Cambridge population-based study of screening for
Type 2 diabetes, we quantified the association between
behaviour change and weight loss in the year after diagnosis
and the subsequent 4 years, in relation to the likelihood of
remission of diabetes at 5-year follow-up.
Methods
Study design and setting
We conducted a cohort study analysis using prospectively
collected data from the ADDITION-Cambridge trial (regis-
tered as ISRCTN86769081). This is a pragmatic, parallel
group cluster randomized controlled trial conducted among
49 general practices in the East of England. Individuals aged
40–69 years who were not known to have diabetes and had a
Cambridge Diabetes Risk Score ≥ 0.17 (corresponding to the
top 25% of participants’ risk distribution) were invited to
attend a stepwise screening programme for Type 2 diabetes,
including initial random capillary glucose and HbA1c testing
followed by a fasting capillary glucose and a confirmatory
oral glucose tolerance test [8–10]. Diagnosis of Type 2
diabetes was based on the 1999 WHO criteria [11].
Exclusion criteria were current pregnancy, lactation, psychi-
atric disease that prevented informed consent, or an illness
with a likely prognosis of <1 year at the time of diabetes
diagnosis. All 867 participants identified by screening agreed
to participate and were randomized at a practice level into
either the intervention group (multifactorial treatment) or
control group (routine care). In the routine care group,
practices were advised to follow current UK national
guidelines for diabetes management [12]. Intensive treatment
comprised more frequent consultations, including a 30-min
annual review, in addition to three 10-min consultations
with a general practitioner and nurse, provision of educa-
tional materials and guidelines, and practice-based academic
detailing sessions, encouraging earlier use of medication to
improve control of risk factors, with a local diabetologist and
a general practitioner opinion leader who described treat-
ment algorithms and targets. A detailed description of the
trial has been reported in previous publications [8,9].
Exposure and outcome measurements
All measures were taken at baseline, 1- and 5-year follow-up.
Physical activity was assessed by self-report using the vali-
dated EPIC Physical Activity Questionnaire (EPAQ-2) [13].
Dietary intake was assessed by self-report using a validated
semi-quantitative food frequency questionnaire, which
enabled estimation of daily intake of total energy, and fat as
a percentage of energy and fibre intake [14,15]. Alcohol intake
and smoking status (categorized as never smoked, ex-smoker
or current smoker) were assessed by self-report via question-
naire. Clinical and biochemical measures were collected by
trained staff following standardized protocols, as previously
described [12,17]. Blood pressure was calculated as the mean
of three measurements using an automatic sphygmomanome-
ter. Body weight and height were measured in light clothing
and without shoes using a scale (SECA) and a fixed rigid
stadiometer, respectively. Venous blood samples were col-
lected for analysis of lipid and HbA1c levels.
Remission was defined as an HbA1c level < 48 mmol/mol
(6.5%) in the absence of any diabetes medication or bariatric
surgery. Information on medication use and a history of
bariatric surgery was self-reported and we also reviewed
patient electronic general practice records. At baseline, none
of the participants included in this cohort were on any
hypoglycaemic agents. We then followed up the whole
cohort for 5 years, regardless of whether they were subse-
quently commenced on medications. Those who went into
remission were by definition not on hypoglycaemic medica-
tion at the 5-year follow-up.
What’s new?
• Biochemical remission of Type 2 diabetes in the absence
of pharmacological or surgical intervention has been
shown to be achievable.
• This has been previously demonstrated in short-term
studies and only in selected populations through inten-
sive weight loss programmes.
• We found that weight loss of ≥10% in the first few
years after diagnosis was strongly associated with
remission of Type 2 diabetes at 5 years.
• This was achieved without intensive lifestyle interven-
tions or extreme calorie restrictions.
• Our findings should inform discussions with people
who have newly diagnosed Type 2 diabetes as a
motivation towards remission of the disease without
restrictive and sometimes unachievable calorie restric-
tions.
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Statistical analysis
Data were pooled from both trial groups and presented for
the whole cohort, adjusted for trial group. Participant
characteristics were summarized at baseline and 1-year
follow-up using mean (SD) values or frequencies. To examine
differences in characteristics between participants who
achieved remission and those who did not, we used the chi-
squared and t-test as appropriate. We also examined differ-
ences between characteristics of participants with and
without missing data; we assessed predictors of missing
weight or remission information by comparing distributions
of factors measured at baseline between those who were and
were not missing weight or remission data. Percentage
weight change over the first year after diagnosis was the
main exposure variable. We also examined percentage
weight change between 1 and 5 years. We constructed
models using percentage weight change in four categories as
follows: no weight change (reference category as  2.5%);
weight gain (≥2.5%); ≤ 2.5–5% weight loss; ≤5–10% weight
loss; and ≥10% weight loss. We also examined weight
change in kilograms as a continuous variable. Change over
the first year, and between 1 and 5 years in physical activity
and diet, as continuous variables (daily intake of total
energy, fat as a percentage of energy, fibre, alcohol and
plasma vitamin C), were then examined. We constructed log
binomial regression models to examine the association
between change in these exposures and 5-year risk of
remission, generating risk ratios and 95% CIs. Multivariable
nested models were then constructed adjusted on a priori
reasoning. Model 1 was adjusted for baseline weight and
follow-up period. Model 2 was additionally adjusted for age,
sex, ethnicity (white or other), education level (full-time
education finished at <16 years or >16 years, occupation
(managerial and professional, intermediate and manual) trial
group, date of diabetes diagnosis and clustering within
practices. Given the possibility that remission might be more
easily achieved amongst participants who had a lower HbA1c
level at baseline, we carried out a subgroup anlaysis that
included only those with an HbA1c level >48 mmol/mol.
Statistical analysis was conducted in STATA version 14 (Stata,
College Station, TX, USA)
Results
Participant characteristics
Of the 867 participants at baseline, 730 (84%) had weight
and HbA1c measures at 5-year follow-up and were included
in the analysis. The mean (SD) age of included participants
was 61 (7) years. Most were men (61%) and white (97%). A
total of 49% had continued in full-time education after the
age of 16 years and 43% reported unskilled or manual
occupations. At the 5-year follow-up, 55% of participants
had initiated hypoglycaemic medications. There were few
differences between those with and without data on weight
change and HbA1c. Compared with included participants,
those with missing data were less likely to have stayed in
education after age 16 years (15% and 11%, respectively).
Between baseline and 1-year follow-up, improvements
were seen in the majority of health behaviours and cardio-
vascular disease risk factors. Baseline participant character-
istics and changes over the first year are shown in Table 1,
stratified according to remission status at 5 years. Diabetes
remission was achieved in 257 participants (30%) in this
cohort. Those who achieved remission were more likely to be
men, smokers and to have remained in full-time education
after age 16 years.
Weight change and remission of diabetes at 5 years
In log binomial regression models, we observed that people
who lost ≥ 10% body weight in the first year after diagnosis
of diabetes were significantly more likely to achieve remis-
sion at 5 years compared to those with stable or increased
weight. We observed similar trends with more modest weight
loss of 5–10% or lower over the first year after diagnosis, but
this was not statistically significant; these results are shown
in Table 2. Similar associations were observed in the analysis
of unit changes in weight, with strong positive correlations
between 1-kg weight loss and remission, as shown in Table 4.
Similar trends were observed between 1 and 5 year follow-up
(Table 3). The greater the amount of weight loss achieved,
the higher the likelihood of remission in all models (Table
5). In the subgroup analysis of participants with a baseline
HbA1c >48 mmol/mol, similar trends were observed between
weight change and remission. This is shown in Tables S1 and
S2.
Behaviour change and remission of diabetes at 5 years
We did not observe any consistent patterns of associations
between unit changes in health behaviours and remission of
diabetes. A positive association with remission was noted
with unit changes in alcohol levels, but these varied between
unadjusted and adjusted models, which are shown in
Table 4.
Discussion
In this prospective cohort study, we investigated the
association between weight loss and remission of Type 2
diabetes at 5 years. We found that modest weight loss of
≥10% in the first year or first 5 years after diagnosis was
strongly associated with remission of Type 2 diabetes.
These findings suggest that remission is achievable without
intensive lifestyle interventions or extreme calorie restric-
tions.
The present findings support and add to previous research
that has demonstrated associations between weight loss and
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remission of Type 2 diabetes [5,7,18]. For example, The
DIRECT trial, also set in UK primary care, reported varying
rates of remission of diabetes, depending on weight loss. The
trial had aimed for a 15-kg weight loss through an intensive
intervention that included withdrawal of antidiabetic and
anti-hypertensive drugs, total diet replacement (825–853
kcal/day formula diet for 3–5 months), stepped food
reintroduction (2–8 weeks), and structured support for
Table 1 Participant characteristics in the ADDITION-Cambridge cohort according to 5-year diabetes remission status
Characteristic
Remission of diabetes Non-remission of diabetes
n Baseline n 1 year n Baseline n 1 year
Sociodemographic
Age, years 257 62 (6.9) _ _ 610 61 (7.3) _ _
White ethnicity, n (%) 257 251 (97) _ _ 610 597 (96) _ _
Men, n (%) 257 152 (59) _ _ 610 232 (38) _ _
Social status, n (%)
Professional 253 83 (33) _ _ 594 194 (33) _ _
Education, n (%)
Full-time education Finished between 16 and 18 years 252 110 (44) _ _ 599 225 (38)
Clinical
BMI, kg/m2 255 33 (5.7) 228 31 (5.5) 607 34 (5.7) 505 33 (5.6)
Waist circumference, cm 257 111 (14.5) 228 107 (14.1) 607 112 (12.9) 505 109 (13.1)
Systolic blood pressure, mmHg 257 141 (19.4) 228 135 (18.1) 608 142 (20.5) 504 137 (18.7)
Total cholesterol, mmol/l 249 5.3 (1.1) 229 4.4 (0.9) 559 5.4 (1.2) 504 4.6 (1.0)
HbA1c 250 225 596 501
mmol/mol 50 (9) 43 (5) 62 (14) 50 (7)
% 6.7 (1.2) 6.1 (0.7) 7.8 (1.8) 6.7 (0.9)
Previous stroke, n (%) 251 7 (2) 224 11 (5) 606 24 (4) 503 25 (5)
Previous myocardial infarction, n (%) 251 15 (6) 225 15 (7) 602 59 (10) 506 47 (9)
Anti-hypertensive medication, n (%) 249 149 (59) 229 157 (68) 601 350 (65) 522 347 (59)
Lipid-lowering medication, n (%) 148 40 (27) 131 84 (64) 609 147 (24) 507 322 (64)
Health behaviour
Physical activity, net MET h/day 256 11.4 (8.2) 227 11.2 (7.5) 608 11.4 (7.2) 520 11.9 (7.6)
Alcohol intake, units/week 254 9 (12) 228 8 (11) 599 7 (11) 508 6 (11)
Current smoker, n (%) 256 38 (15) 229 27 (12) 610 119 (20) 515 84 (16)
Diet
Total energy, kcal/day 254 1941 (654) 225 1710 (597) 601 1977 (739) 518 1720 (607)
Energy from fat, % 254 32 (6) 225 30 (7) 601 33 (6) 518 31 (6)
Fibre, g/day 254 17 (7) 225 19 (11) 601 17 (7) 518 19 (11)
Vitamin C intake, mg/day 254 133 (71) 225 142 (99) 601 128 (66) 518 139 (107)
Data are mean (SD), unless otherwise stated.
Table 2 Association between percentage weight change category in the first year after diagnosis, and the risk of remission at 5 years in the
ADDITION-Cambridge study
% weight change category n Risk ratio 95% CI p
Unadjusted No change (2.5% change from baseline) 867 266 1
Weight gain (≥2.5%) 207 0.89 0.64 1.21 0.44
Weight loss >2.5 to <5% 151 1.01 0.72 1.40 0.97
Weight loss ≥5 to <10% 138 1.32 0.97 1.79 0.07
Weight loss ≥10% 105 1.85 1.39 2.45 <0.01
Adjusted model 1* No change (2.5% change from baseline) 670 226 1
Weight gain (≥2.5%) 97 0.77 0.50 1.17 0.23
Weight loss >2.5 to <5% 140 1.01 0.72 1.40 0.95
Weight loss ≥5 to <10% 118 1.29 0.94 1.77 0.11
Weight loss ≥10% 89 1.76 1.31 2.35 <0.01
Adjusted model 2† No change (2.5% change from baseline) 648 221 1
Weight gain (≥2.5%) 96 0.79 0.52 1.21 0.28
Weight loss >2.5 to <5% 135 1.00 0.71 1.40 0.99
Weight loss ≥5 to <10% 113 1.24 0.91 1.72 0.17
Weight loss ≥10% 83 1.77 1.32 2.38 <0.01
*Model 1 adjusted for baseline weight and follow-up period. † Model 2 adjusted for baseline weight, follow-up period, age, sex, ethnicity,
socio-economic group, education level, occupation, trial group, clustering of practices and date of diabetes diagnosis
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long-term weight loss maintenance. On average, 10 kg
(15%) of weight was lost in the intervention group and half
of the participants achieved remission. [7,19]. Other studies
with similar intensive interventions in highly selected popu-
lations include the Counterbalance trial and the Look
AHEAD trial. The Look AHEAD trial did not report
remission as a primary outcome, but did include intensive
support through dietary and physical activity programmes
which resulted in remission. Whilst our observational find-
ings are consistent with these trials, the specific amount of
weight loss required to achieve remission varies. Most
previous studies advocate significant weight loss (>15%),
with the DIRECT, Counterbalance and Look AHEAD trials
reporting between 5- and 20-kg weight loss in order to
achieve diabetes remission [5,7]. However, while baseline
HbA1c values were lower in our screen-detected cohort, our
results suggest that more modest weight loss of >10% is
associated with a higher likelihood of remission if this occurs
early in the disease trajectory. This may provide some
rationale for motivating people with newly diagnosed Type 2
diabetes to lose weight rather than focusing on specific and
potentially unachievable weight targets. Previous studies
have shown that, when attempting to lose weight, people
often set unrealistically high weight loss goals that could be
detrimental to success, and evidence on whether weight loss
counselling with specific targets is always successful is
inconsistent [20]. Indeed, the DIRECT trial did not manage
to achieve the weight loss targets intended for most partic-
ipants, with only 24% managing the 15-kg target weight loss
despite the intensive support. Furthermore, these
Table 3 Association between percentage weight change category between 1 and 5 years after diagnosis, and the risk of remission at 5 years in the
ADDITION-Cambridge study
% weight change category n Risk ratio 95% CI p
Unadjusted No change (2.5% change from baseline) 867 242 1
Weight gain (≥2.5%) 392 0.75 0.57 0.98 0.05
Weight loss >2.5 to <5% 93 1.24 0.90 1.74 0.19
Weight loss ≥5 to <10% 103 1.36 0.99 1.85 0.05
Weight loss ≥10% 37 2.30 1.71 3.09 <0.01
Adjusted model 1* No change (2.5% change from baseline) 670 227 1
Weight gain (≥2.5%) 230 0.86 0.64 1.17 0.33
Weight loss >2.5 to <5% 88 1.24 0.89 1.76 0.22
Weight loss ≥5 to <10% 93 1.39 1.01 1.91 0.04
Weight loss ≥10% 32 2.50 1.86 3.37 <0.01
Adjusted model 2† No change (2.5% change from baseline) 648 222 1
Weight gain (≥2.5%) 225 0.85 0.63 1.15 0.30
Weight loss >2.5 to <5% 82 1.35 0.95 1.91 0.09
Weight loss ≥5 to <10% 89 1.43 1.03 1.98 0.02
Weight loss ≥10% 30 2.43 1.78 3.31 <0.01
*Model 1 adjusted for 1-year weight and follow-up period.
†Model 2 adjusted for 1-year weight, follow-up period, age, sex, ethnicity, socio-economic group, education level, occupation, trial group,
clustering of practices and date of diabetes diagnosis.
Table 4 Associations between change in weight and health behaviours in the first year after diagnosis and the risk of remission at 5 years
Variable
Unadjusted model 1 * model 2 †
n
Risk
ratio 95% CI P n
Risk
ratio 95% CI p n
Risk
ratio 95% CI p
Weight (kg) 730 1.06 1.03 1.09 <0.01 635 1.07 1.04 1.11 <0.01 632 1.07 1.04 1.11 <0.01
Physical activity (net
MET h/day)
747 0.99 0.96 1.01 0.37 702 0.99 0.96 1.01 0.45 702 0.98 0.96 1.02 0.50
Alcohol intake (units/
week)
726 1.00 0.98 1.03 0.65 683 1.03 1.00 1.07 0.04 683 1.04 1.00 1.08 0.04
Current smoker 744 0.72 0.30 1.73 0.47 699 0.69 0.23 1.89 0.50 699 0.69 0.23 2.01 0.50
Total energy (kcal/day) 736 1.00 0.99 1.00 0.44 692 1.00 0.99 1.00 0.38 692 1.00 0.99 1.00 0.38
Energy from fat (%) 736 1.00 0.98 1.03 0.47 692 1.00 0.97 1.02 0.91 692 0.99 0.97 1.02 0.91
Fibre (g/day) 736 1.00 0.99 1.01 0.79 692 1.00 0.97 1.03 0.90 692 1.00 0.97 1.03 0.90
Vitamin C intake
(mg/day)
739 0.99 0.99 1.00 0.96 692 0.99 0.99 1.00 0.90 692 1.00 0.99 1.00 0.58
*Model 1 adjusted for baseline health behaviour and follow-up period.
†Model 2 adjusted for baseline health behaviour, follow-up period, age, sex, ethnicity, socio-economic group, education level, occupation,
trial group, clustering of practices and date of diabetes diagnosis.
ª 2019 The Authors.
Diabetic Medicine published by John Wiley & Sons Ltd on behalf of Diabetes UK 685
Research article DIABETICMedicine
interventions are unlikely to be scalable to the wider
population because of their intensity and cost and the limited
availability of facilitators [7]. Our data suggest that, in
addition to extending availability of intensive weight loss
interventions, policymakers should consider a range of
accessible approaches targeting weight loss amongst people
with newly diagnosed diabetes.
Finally, while we observed associations between weight
change and remission, we did not observe consistent
associations between behaviour change and remission. This
might be attributable to the differential precision of the
exposure measurements, most of which were self-reported
and therefore subject to error and bias. For example, we
found that self-reported alcohol intake was associated with
remission. Although there is some mixed evidence in the
literature suggesting that moderate alcohol intake could be
associated with positive cardiovascular outcomes, our
findings were not consistent between adjusted and unad-
justed models [21]. It is therefore unlikely to be a true
association. It could be due to chance or residual con-
founding.
The present study included people with Type 2 diabetes
from a large population-based sample across an extensive
geographical area in the East of England in routine clinical
follow-up. We used measures of remission that are available
in clinical practice to allow translation of our findings to
practice. There was heterogeneity in this cohort with regard
to socio-economic groups, disease severity and health
behaviours. There were also no specific dietary or physical
activity restrictions for participants. This means that the
study is generalizable to wider diabetes populations outside
clinical trial cohorts; however, the sample was not ethnically
diverse, comprising predominantly white European partici-
pants, which reflects the local population. Other strengths
include the duration of follow-up which was 5 years; most
previous remission studies were of < 12 months’ duration.
Also, participant retention in the present cohort was high,
being 95% at 1-year follow-up and 83% at the 5-year
follow-up. Behaviours were measured using previously val-
idated questionnaires and repeated measures with the same
instruments, reducing our concerns about measurement
error. We did, however, conduct a number of hypothesis
tests, so chance remains a plausible explanation for our
findings.
In conclusion, remission of Type 2 diabetes is achievable in
the longer term with modest weight loss of >10% early in the
disease trajectory. This can be achieved without intensive
interventions in free-living populations. Our findings should
inform discussions with people who have newly diagnosed
Type 2 diabetes as motivation towards remission of the
disease without restrictive and sometimes unachievable
calorie restrictions. Further work is needed to replicate these
findings in more ethnically and socially diverse populations.
Further examination will need to include an assessment of
the relationship between remission and longer-term clinical
outcomes, such as mortality.
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